Fatigue after thyroidectomy or radio-iodine ablation - when the thyroid is gone but the tiredness stays
Updated: Sep 28
Why a normal TSH does not always mean that every patient feels restored after thyroidectomy or radioiodine
Most pathways recover smoothly. In a minority, the laboratory result and lived experience do not line up so neatly.
For most people, levothyroxine after total thyroidectomy or radioiodine works remarkably well. The dose settles, the thyroid-stimulating hormone (TSH) returns to its target range and ordinary life resumes. The tablet becomes a small morning habit rather than the main character in the day.
A minority have a very different experience. They describe relentless tiredness, sleepiness, reduced stamina, slowed thinking, poor memory, difficulty managing weight or a loss of psychological wellbeing. Their TSH may look excellent. They may still say, with striking consistency, “I have never felt like myself since my thyroid was removed.”
That account should not be dismissed. It does mean that the person in front of us deserves a fuller assessment than a congratulatory glance at the laboratory screen.
The figure that needs careful wording
Persistent symptoms despite a normal TSH are often quoted in roughly 10 to 20 percent of levothyroxine-treated patients, although estimates vary with the population, the questions asked and the definition of “persistent.” Some modern reviews quote 5 to 10 percent. These studies include people with several causes of hypothyroidism, so they do not give a clean, universal prevalence for patients who are completely without a thyroid.
A separate and highly relevant finding comes from athyreotic patients, meaning people with no functioning thyroid tissue. In the 2011 study by Gullo and colleagues, more than one in five had either FT3 or FT4 outside the reference range despite a normal TSH. That was a biochemical finding, not a count of people with disabling fatigue. The two “one in five” ideas are related, but they are not interchangeable.
The honest conclusion is therefore modest but important: persistent symptoms are common enough to discuss before an irreversible treatment, and the physiology gives us a credible reason to investigate them seriously when they occur.
What the thyroid normally contributes
The thyroid makes mainly thyroxine, or T4, and a smaller amount of triiodothyronine, or T3. T4 is the longer-lived circulating supply. T3 is the more biologically active signal that binds thyroid-hormone receptors and influences energy use, temperature, heart function, muscle, mood and cognition.
Much of the body’s T3 is made outside the thyroid. Enzymes called deiodinases remove one iodine atom from T4 and convert it into T3. Different tissues use different transporters and deiodinases, allowing a degree of local control. The brain, skeletal muscle and other tissues do not all handle thyroid hormone in precisely the same way.
The normal thyroid also releases some T3 directly. Once the entire gland has been removed or destroyed, that direct contribution disappears. Every molecule of circulating T4 comes from the levothyroxine tablet, and T3 production depends far more heavily on conversion elsewhere. Most bodies make that arrangement work. Biology, however, has never promised identical plumbing in every house.
Why TSH can be normal while the hormonal pattern is different
TSH is an excellent marker and remains the main safety and dosing test in primary hypothyroidism. It tells us how the pituitary is responding to the thyroid-hormone signal it receives. It does not directly measure thyroid-hormone action in every tissue.
This matters because the pituitary is particularly capable of converting T4 to T3 locally. A levothyroxine dose can therefore provide enough local T3 to reassure the pituitary and normalise TSH, while the circulating balance of FT4 and FT3 remains different from that of a person with an intact thyroid. A useful analogy is that the pituitary is a sensitive central thermostat; it is not a temperature sensor in every room.
Gullo and colleagues compared 1,811 athyreotic patients taking levothyroxine, all with TSH within 0.4 to 4.0 mU/L, with 3,875 people who had normal thyroid function. The treated group had a higher median FT4, a lower median FT3 and a lower FT3 to FT4 ratio. Specifically, 15.2 percent had FT3 below the control-derived normal range, 7.2 percent had FT4 above it and 29.6 percent had an unusually low FT3 to FT4 ratio. A normal TSH had not recreated the native circulating hormone pattern in everyone.
That study did not show that the altered ratio caused symptoms, nor did it measure thyroid hormone inside human brain or muscle. It showed something narrower and valuable: levothyroxine can normalise TSH without reproducing the biochemical state created by a functioning thyroid.
Why one person feels well and another does not
There is unlikely to be a single explanation. Several pathways may overlap, and their relative importance probably differs from one patient to another.
T4 to T3 conversion and tissue signalling may vary. Higher circulating T4 and loss of direct thyroidal T3 can leave some patients with lower circulating T3 or a lower T3 to T4 ratio. Whether this creates inadequate T3 action in a particular human tissue is plausible but not yet directly measurable in routine practice.
Genetics may contribute. The best-known candidate is the Thr92Ala variant in DIO2, the gene for type 2 deiodinase. Some experimental and subgroup findings are intriguing, but larger clinical studies have been inconsistent. DIO2 or transporter genotyping cannot currently identify a reliable “T3 responder.”
The original disease still matters. Graves disease can affect wellbeing beyond a single hormone result, and thyroid eye disease, autoimmunity, anxiety after a severe illness and the time needed to recover may all influence quality of life.
Replacement may be imperfect for practical reasons. Missed tablets, changing brands, taking levothyroxine with food or coffee, and interference from iron, calcium, antacids or gastrointestinal disease can all disturb absorption.
Another condition may be present at the same time. Anaemia, iron or vitamin B12 deficiency, coeliac disease, diabetes, sleep apnoea, depression, menopause, medication effects and other chronic illness can produce an almost identical symptom list. After thyroid surgery, calcium and parathyroid function deserve particular attention.
Looking for these alternatives is how we avoid missing a treatable cause while keeping the thyroid question open.
What the radioiodine quality of life study tells us
A long-term Swedish cohort reported by Törring and colleagues followed 1,186 people with Graves disease approximately 6 to 10 years after treatment. Those who had received radioiodine reported worse thyroid-related and general quality of life across many domains than those treated with antithyroid drugs or surgery.
The finding deserves attention, but it does not prove that radioiodine caused the poorer outcome or that low T3 was the mechanism. Treatment was not randomised, the groups differed in age and comorbidity, the course of disease may have been more difficult in those selected for radioiodine, and thyroid status at the quality-of-life assessment was not available. The study raises a serious question. It does not close the case.
The part of definitive treatment we should discuss more clearly
Radioiodine and surgery are excellent treatments. They can control dangerous thyrotoxicosis, remove a large or compressive goitre, address suspicious nodules or cancer, and solve problems that antithyroid medication cannot safely solve. This article is not an argument against either treatment.
It is an argument for complete consent. “You will need one levothyroxine tablet every morning” is accurate for many people, but it can make lifelong hormone replacement sound like an administrative footnote. For a minority, it becomes the dominant consequence of treatment.
A balanced consent conversation might include the following:
“Most people feel well on levothyroxine after their thyroid is removed or destroyed. A minority still experience fatigue or slowed thinking despite satisfactory blood tests. We do not fully understand why. Persistent symptoms deserve careful assessment, and selected patients may be offered other replacement strategies.”
For a person with Graves disease who is doing well on a low maintenance dose of carbimazole, has no large goitre, suspicious nodule, troublesome eye disease or urgent reason for definitive treatment, the possibility of not feeling the same after complete ablation is a legitimate factor to place on the scales. It must sit alongside relapse risk, medication toxicity, fertility and pregnancy plans, eye disease, patient preference and the clinical need for reliable control.
If the thyroid is already gone and the fatigue remains
There is no single blood test that proves tissue hypothyroidism, and there is no responsible shortcut to T3. A structured review is much more useful than either reflexively increasing levothyroxine or declaring the case closed.
1. Check the basics carefully. Confirm a stable levothyroxine dose, consistent timing, adherence, brand or formulation changes, and separation from food, coffee, calcium, iron and other interacting medicines. Recheck TSH after an appropriate steady period following any change.
2. Optimise levothyroxine before replacing it. The 2023 British consensus suggests aiming for TSH toward the lower part of the reference range, around 0.3 to 2.0 mU/L, for about six months before judging the response. A persistently suppressed TSH should be avoided because excess thyroid hormone increases the risks of atrial fibrillation and bone loss.
3. Look deliberately for other causes. Assessment may include a history and examination plus selected tests such as full blood count, renal and liver profile, calcium, HbA1c, ferritin, vitamin B12, vitamin D and coeliac screening. Sleep apnoea, mood, menopause and adrenal disease should be assessed when the clinical picture suggests them. Testing should be guided by the patient, not ordered as a laboratory treasure hunt.
4. Measure what matters to the patient. Record the dominant symptoms and their effect on work, exercise, cognition, relationships and daily functioning. A validated questionnaire such as ThyPRO before and after a treatment change can make an otherwise slippery outcome more visible.
5. Consider a supervised LT4 and LT3 trial in selected patients. UK consensus accepts that a 3 to 6 month trial may be reasonable after confirmed overt hypothyroidism, adequate LT4 treatment and exclusion of important alternative causes. An endocrinologist should initiate and monitor it, usually by reducing LT4 while introducing a small, often divided dose of liothyronine and keeping TSH within range.
6. Keep an exit rule. If a carefully monitored trial produces no meaningful and sustained improvement, liothyronine should be stopped and levothyroxine monotherapy resumed. More hormone is not automatically better hormone.
Why T3 is not a simple rescue tablet
Liothyronine has a shorter half-life than levothyroxine and can create peaks after each dose. Too much can cause palpitations, tremor, anxiety, sweating and insomnia; sustained over-replacement raises concern about arrhythmia and accelerated bone loss. Long-term safety data are less extensive than for levothyroxine. Randomised trials have not shown a consistent population-level advantage of LT4 and LT3 combination therapy over LT4 alone for mood, cognition or quality of life. Many trials were small, used different formulations and schedules, did not reproduce normal T3 physiology, and often enrolled broad hypothyroid populations rather than specifically selecting the most symptomatic athyreotic patients. The absence of a consistent average benefit does not prove that no individual can benefit, but it makes disciplined selection and measurement essential.
Current genetics do not solve that selection problem. DIO2 testing and FT3 to reverse T3 ratios are not validated tools for choosing treatment. Desiccated thyroid extract is also not recommended by the British consensus. Liothyronine should not be used in pregnancy, and patients should never add T3 bought online or alter replacement without medical supervision.
A normal TSH is valuable but it is not a verdict on wellbeing
The pendulum can swing too far in either direction. Ignoring TSH and treating symptoms with progressively higher thyroid-hormone doses can cause real harm. Ignoring symptoms because TSH is normal can also cause harm: missed diagnoses, lost trust and years of preventable disability.
The sensible middle is both biochemical and human. Use TSH to protect the patient from under- and over-replacement. Use careful history, examination, selected investigations and patient-reported outcomes to understand the person whom the TSH cannot fully describe.
For most patients, life after thyroidectomy or radioiodine is entirely ordinary on levothyroxine. That reassurance remains true. The smaller group who struggle should hear something equally true: their experience is recognised, the physiology is plausible, uncertainty remains, and a thoughtful clinical pathway exists.
Questions patients may wish to ask before definitive treatment
Why is radioiodine or surgery being recommended in my particular case?
Is continued antithyroid medication a reasonable option for me, and what are its risks?
Will the proposed treatment leave me completely without functioning thyroid tissue?
What symptoms should prompt a review after treatment, even if my TSH is normal?
Who will optimise my replacement and investigate persistent symptoms if I do not feel well?
Key evidence and further reading
Medical note This article is for general information and does not replace individual medical assessment. Thyroid-hormone doses should be changed only with an appropriately qualified clinician.
Comments